American Oncology Network, Inc.

First-quarter 2024 revenue was $364.3 million, up from $303.7 million a year ago, an increase of $60.6 million or 20%. Revenue per encounter increased 12.8%, contributing $59.7 million, and patient encounters rose 6.2%, contributing $18.7 million. Cost of revenue was $354.9 million versus $278.5 million in the prior-year period, and the company reported a net loss before non-controlling interest of $24.9 million versus a $1.5 million net loss last year. Adjusted EBITDA was $2 million versus $4 million a year ago. At quarter end, total liquidity was $132.7 million, including $74.9 million of cash and cash equivalents and $30.1 million of short-term marketable securities. The company did not provide explicit next-quarter or full-year financial guidance on the call.

Todd Schonherz said the company carried forward momentum from the prior year and continued executing its growth plan through acquisitions, provider additions, and expansion in existing markets like Texas and Maryland. He framed AON’s model as differentiated by operational autonomy, purchasing scale, integrated pharmacy and lab, centralized back office, and technology, and said these advantages help practices remain competitive while improving patient care. He was upbeat about MiBA and NOVA as new technology-enabled enhancements and repeatedly emphasized that AON is positioned as a national destination for community oncology practices.

David Gould reported Q1 revenue of $364.3 million, up 20% year over year, with the increase driven mainly by higher revenue per encounter and higher patient encounters. He noted cost of revenue rose to $354.9 million, largely due to drug and medical supply costs, higher cost per encounter, and $13.3 million of equity-based compensation included in cost of revenue. He also detailed liquidity of $132.7 million, comprising $74.9 million of cash and cash equivalents, $30.1 million of short-term marketable securities, and borrowing capacity under the PNC facility and line of credit; $81.3 million was outstanding under the PNC loan facility at 7.1%, while the line of credit was undrawn.

There was no substantive analyst Q&A in the transcript provided, so no investor concerns or management clarifications were discussed beyond the prepared remarks. The only additional commentary was management’s closing emphasis on continuing investments in the platform and expecting to update investors on second-quarter results next quarter.